What does CUSIP 720795103 represent in this 13F holders report?

CUSIP 720795103 is the security identifier for PIRS - PIERIS PHARMACEUTICALS INC - COM used to aggregate holder disclosures.

How many institutions held PIRS - PIERIS PHARMACEUTICALS INC - COM in Q1 2023?

60 institutional investors reported PIRS - PIERIS PHARMACEUTICALS INC - COM for Q1 2023. Use the holders table for investor-level position and value details.

PIERIS PHARMACEUTICALS INC - COM (PIRS)

CUSIP: 720795103

Q1 2023 13F Holders as of 31 Mar 2023

Security type / class: Equity / COM
Total 13F shares: 34,246,696
Total 13F value: $33,405,987
Share change: -1,161,886
Put/Call ratio: 5.6%
SEC-reported price per share: $0.98
Number of holders: 60
Value change: -$1,152,067
Number of buys: 18
Number of sells: 28

Security key

720795103

Report period

Q1 2023

Institutions

Top holders

PIRS full security history Ownership snapshot Full 13F holder table PALVELLA THERAPEUTICS, INC. SEC filings PALVELLA THERAPEUTICS, INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of PIRS - PIERIS PHARMACEUTICALS INC - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Lynx1 Capital Management LP

Disclosed value leader

Lynx1 Capital Management LP

Comparable rows

0/15

Latest evidence

31 Dec 2022

13F Highest disclosed value: $5,853,728 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Lynx1 Capital Management LP has the largest disclosed position value at $5.85M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Lynx1 Capital Management LP's linked filing trail.

Disclosed position value Top 5

Lynx1 Capital Management LP $5.85M

BVF INC/IL $5.28M

Aquilo Capital Management, LLC $4.73M

BANK OF AMERICA CORP /DE/ $3.81M

MARSHALL WACE, LLP $2.49M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Lynx1 Capital Management LP	13F Company 13F	— denominator unverified	$5,853,728 5,628,585 shares	—	31 Dec 2022
BVF INC/IL	13F Company 13F	— denominator unverified	$5,283,533 5,080,320 shares	—	31 Dec 2022
Aquilo Capital Management, LLC	13F Company 13F	— denominator unverified	$4,734,991 4,552,876 shares	—	31 Dec 2022
BANK OF AMERICA CORP /DE/	13F Company 13F	— denominator unverified	$3,812,295 3,665,668 shares	—	31 Dec 2022
MARSHALL WACE, LLP	13F Company 13F	— denominator unverified	$2,487,718 2,392,036 shares	—	31 Dec 2022
CITADEL ADVISORS LLC	13F Company 13F	— denominator unverified	$2,128,007 2,046,161 shares	—	31 Dec 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

34,246,696

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q1 2023 Shares	Share Diff	Share Chg %	Q1 2023 value	Q1 2023 value	Value change	Value Chg %